Skip to main content
. 2020 Feb 18;22(6):904–915. doi: 10.1111/dom.13984

Figure 1.

Figure 1

Summary of randomized allocation of patients to treatment in the UK Prospective diabetes study. SU, sulphonylurea; T2D, type 2 diabetes. aConventional treatment policy in the UKPDS. bThese patients were included in the main trial analysis (UKPDS 33). cUKPDS 34. dDefined as fasting plasma glucose 6.1–15 mmol/L (110–270 mg/dL) without symptoms of hyperglycaemia. Adapted from references7, 8 with permission from Elsevier